Format
Sort by

Send to

Choose Destination

Search results

Items: 7

1.

Phase 2 study of sodium phenylbutyrate in ALS.

Cudkowicz ME, Andres PL, Macdonald SA, Bedlack RS, Choudry R, Brown RH Jr, Zhang H, Schoenfeld DA, Shefner J, Matson S, Matson WR, Ferrante RJ; Northeast ALS and National VA ALS Research Consortiums..

Amyotroph Lateral Scler. 2009 Apr;10(2):99-106. doi: 10.1080/17482960802320487.

PMID:
18688762
2.

Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice.

Del Signore SJ, Amante DJ, Kim J, Stack EC, Goodrich S, Cormier K, Smith K, Cudkowicz ME, Ferrante RJ.

Amyotroph Lateral Scler. 2009 Apr;10(2):85-94. doi: 10.1080/17482960802226148.

PMID:
18618304
3.

Design, power, and interpretation of studies in the standard murine model of ALS.

Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, Kelly N, Bostrom A, Theodoss J, Al-Nakhala BM, Vieira FG, Ramasubbu J, Heywood JA.

Amyotroph Lateral Scler. 2008;9(1):4-15. doi: 10.1080/17482960701856300.

PMID:
18273714
4.

Neuroprotective agents for clinical trials in ALS: a systematic assessment.

Traynor BJ, Bruijn L, Conwit R, Beal F, O'Neill G, Fagan SC, Cudkowicz ME.

Neurology. 2006 Jul 11;67(1):20-7. Review.

PMID:
16832072
5.

Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis.

Petri S, Kiaei M, Kipiani K, Chen J, Calingasan NY, Crow JP, Beal MF.

Neurobiol Dis. 2006 Apr;22(1):40-9.

PMID:
16289867
6.

Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice.

Ryu H, Smith K, Camelo SI, Carreras I, Lee J, Iglesias AH, Dangond F, Cormier KA, Cudkowicz ME, Brown RH Jr, Ferrante RJ.

J Neurochem. 2005 Jun;93(5):1087-98. Erratum in: J Neurochem. 2006 Feb;96(3):908.

7.
Items per page

Supplemental Content

Loading ...
Support Center